Cellectar Biosciences GAAP EPS of -$3.39 beats by $0.31

* Cellectar Biosciences press release [https://seekingalpha.com/pr/20200781-cellectar-biosciences-reports-second-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:CLRB [https://seekingalpha.com/symbol/CLRB]): Q2 GAAP EPS of -$3.39 beats by $0.31.
* As of June 30, 2025, the company had cash and cash equivalents of approximately $11.0 million, compared to $23.3 million as of December 31, 2024, which includes $2.3 million in net proceeds received in connection with the company’s June warrant exercises but does not reflect net proceeds of approximately $5.8 million from the July 2025 offering.

MORE ON CELLECTAR BIOSCIENCES

* Cellectar Biosciences announces one-for-thirty reverse stock split [https://seekingalpha.com/news/4459704-cellectar-biosciences-announces-one-for-thirty-reverse-stock-split]
* Cellectar Biosciences enters into common stock agreements to raise $2.5 million [https://seekingalpha.com/news/4455853-cellectar-biosciences-enters-into-common-stock-agreements-to-raise-25-million]
* Seeking Alpha’s Quant Rating on Cellectar Biosciences [https://seekingalpha.com/symbol/CLRB/ratings/quant-ratings]
* Historical earnings data for Cellectar Biosciences [https://seekingalpha.com/symbol/CLRB/earnings]
* Financial information for Cellectar Biosciences [https://seekingalpha.com/symbol/CLRB/income-statement]